Lifecore Biomedical, Inc. LFCR
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 5.31% | 5.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 5.31% | 5.31% |
| Cost of Revenue | -- | -- | -- | 10.29% | 10.29% |
| Gross Profit | -- | -- | -- | -4.06% | -4.06% |
| SG&A Expenses | -- | -- | -- | -7.55% | -7.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 3.64% | 3.64% |
| Operating Income | -- | -- | -- | 32.49% | 32.49% |
| Income Before Tax | -- | -- | -- | -654.87% | -654.87% |
| Income Tax Expenses | -- | -- | -- | 472.86% | 472.86% |
| Earnings from Continuing Operations | -- | -- | -- | -668.69% | -668.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -596.83% | -596.83% |
| EBIT | -- | -- | -- | 32.49% | 32.49% |
| EBITDA | -- | -- | -- | 118.52% | 118.52% |
| EPS Basic | -- | -- | -- | -582.76% | -582.76% |
| Normalized Basic EPS | -- | -- | -- | -293.15% | -293.15% |
| EPS Diluted | -- | -- | -- | -2,219.60% | -2,219.60% |
| Normalized Diluted EPS | -- | -- | -- | -433.62% | -433.62% |
| Average Basic Shares Outstanding | -- | -- | -- | 19.16% | 19.16% |
| Average Diluted Shares Outstanding | -- | -- | -- | 8.45% | 8.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |